Fasudil (Raya Therapeutic)

法舒地尔 (Raya Therapeutic)

Report date: 2025/01/10 20:00:59

Base Information

Drug NameFasudil (Raya Therapeutic)
Drug Alias NameFasudil hydrochloride hydrate IV solution (Raya Therapeutic)RT-1968
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho-associated protein kinase 1 inhibitorsRho-associated protein kinase 2 inhibitorsProtein kinase C inhibitors
TargetsRho-associated protein kinase 1Rho-associated protein kinase 2Protein kinase C
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanySwitzerlandFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Medical Center Gottingen
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center Goettingen
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A